Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 6/20 | 0.47 |
| ▸ | MAOA | P21397 | 4/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11732154 | 0.92 | MAOA (0.52) | HRH3MAOBMAOA | |
| SCHEMBL9223479 | 0.92 | MAOA (0.52) | HRH3MAOBMAOA | |
| SCHEMBL8597524 | 0.87 | HRH3 (0.49) | PTGS2HRH3MAOBMAOAPDK2 | |
| SCHEMBL11741286 | 0.87 | MAOA (0.54) | HRH3MAOBMAOA | |
| SCHEMBL4813615 | 0.86 | MAPK14 (0.52) | PTGS2HRH3CASP1CASP7HSD17B10 | |
| SCHEMBL4403542 | 0.84 | CASP1 (0.44) | PTGS2HRH3CASP1CASP7HSD17B10 | |
| SCHEMBL4806938 | 0.83 | HRH3 (0.43) | PTGS2HRH3CASP1CASP7HSD17B10 | |
| SCHEMBL21461282 | 0.81 | HRH3 (0.51) | HRH3MAOBMAOA | |
| SCHEMBL10685922 | 0.81 | ROCK1 (0.52) | HRH3MAOBMAOA | |
| SCHEMBL1339241 | 0.80 | MAOB (0.44) | PTGS2HRH3CASP1CASP7HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2006271-A9 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2009-07-29 | — | — | EP | disclosed |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-2006271-A2 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2008-12-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | LTB4R2, LTC4S, LTB4R | PTGS2 18/4885HRH3 312/4885CASP1 2124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.